Aura Biosciences (AURA) Competitors

Aura Biosciences logo
$7.15 -0.07 (-0.97%)
Closing price 04:00 PM Eastern
Extended Trading
$7.14 -0.01 (-0.14%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AURA vs. ACAD, IDYA, VCEL, ZLAB, and XNCR

Should you buy Aura Biosciences stock or one of its competitors? Aura Biosciences's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), IDEAYA Biosciences (IDYA), Vericel (VCEL), Zai Lab (ZLAB), and Xencor (XNCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aura Biosciences compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

ACADIA Pharmaceuticals has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$1.07B2.95$391M$2.118.68
Aura BiosciencesN/AN/A-$106.19M-$1.64N/A

ACADIA Pharmaceuticals has a net margin of 30.13% compared to Aura Biosciences' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 8.90% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals30.13% 8.90% 6.86%
Aura Biosciences N/A -64.68%-56.08%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals presently has a consensus price target of $31.34, suggesting a potential upside of 71.08%. Aura Biosciences has a consensus price target of $17.50, suggesting a potential upside of 144.76%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
0 Sell rating(s)
5 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.72
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Aura Biosciences had 2 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 18 mentions for Aura Biosciences and 16 mentions for ACADIA Pharmaceuticals. Aura Biosciences' average media sentiment score of 0.64 beat ACADIA Pharmaceuticals' score of 0.24 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
5 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aura Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive

ACADIA Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Summary

ACADIA Pharmaceuticals beats Aura Biosciences on 10 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Aura Biosciences has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -1,157.18%. IDEAYA Biosciences' return on equity of -39.78% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
IDEAYA Biosciences-1,157.18% -39.78% -36.25%
Aura Biosciences N/A -64.68%-56.08%

IDEAYA Biosciences presently has a consensus price target of $49.55, indicating a potential upside of 80.82%. Aura Biosciences has a consensus price target of $17.50, indicating a potential upside of 144.76%. Given Aura Biosciences' higher possible upside, analysts clearly believe Aura Biosciences is more favorable than IDEAYA Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEAYA Biosciences
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Aura Biosciences had 4 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 18 mentions for Aura Biosciences and 14 mentions for IDEAYA Biosciences. Aura Biosciences' average media sentiment score of 0.64 beat IDEAYA Biosciences' score of 0.34 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IDEAYA Biosciences
1 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Aura Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 1.9% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aura Biosciences has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEAYA Biosciences$218.71M12.11-$113.70M-$4.49N/A
Aura BiosciencesN/AN/A-$106.19M-$1.64N/A

IDEAYA Biosciences has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Summary

IDEAYA Biosciences and Aura Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to Vericel?

Vericel (NASDAQ:VCEL) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Aura Biosciences had 3 more articles in the media than Vericel. MarketBeat recorded 18 mentions for Aura Biosciences and 15 mentions for Vericel. Vericel's average media sentiment score of 0.75 beat Aura Biosciences' score of 0.64 indicating that Vericel is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vericel
6 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aura Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive

Vericel has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$276.26M10.69$16.52M$0.6490.44
Aura BiosciencesN/AN/A-$106.19M-$1.64N/A

Vericel presently has a consensus target price of $62.00, indicating a potential upside of 7.12%. Aura Biosciences has a consensus target price of $17.50, indicating a potential upside of 144.76%. Given Aura Biosciences' higher possible upside, analysts clearly believe Aura Biosciences is more favorable than Vericel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

96.8% of Aura Biosciences shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vericel has a net margin of 10.27% compared to Aura Biosciences' net margin of 0.00%. Vericel's return on equity of 9.09% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Vericel10.27% 9.09% 6.68%
Aura Biosciences N/A -64.68%-56.08%

Vericel has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Summary

Vericel beats Aura Biosciences on 12 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

In the previous week, Aura Biosciences had 5 more articles in the media than Zai Lab. MarketBeat recorded 18 mentions for Aura Biosciences and 13 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.75 beat Aura Biosciences' score of 0.64 indicating that Zai Lab is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zai Lab
5 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Aura Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive

Aura Biosciences has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$460.16M6.40-$175.54M-$1.79N/A
Aura BiosciencesN/AN/A-$106.19M-$1.64N/A

Zai Lab currently has a consensus price target of $37.25, indicating a potential upside of 58.31%. Aura Biosciences has a consensus price target of $17.50, indicating a potential upside of 144.76%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Zai Lab.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Zai Lab has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Aura Biosciences has a net margin of 0.00% compared to Zai Lab's net margin of -44.91%. Zai Lab's return on equity of -31.15% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Zai Lab-44.91% -31.15% -18.17%
Aura Biosciences N/A -64.68%-56.08%

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 1.9% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Zai Lab beats Aura Biosciences on 9 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Xencor?

Aura Biosciences (NASDAQ:AURA) and Xencor (NASDAQ:XNCR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, Aura Biosciences had 11 more articles in the media than Xencor. MarketBeat recorded 18 mentions for Aura Biosciences and 7 mentions for Xencor. Xencor's average media sentiment score of 0.88 beat Aura Biosciences' score of 0.64 indicating that Xencor is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aura Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive
Xencor
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Xencor has higher revenue and earnings than Aura Biosciences. Xencor is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aura BiosciencesN/AN/A-$106.19M-$1.64N/A
Xencor$125.58M20.62-$91.92M-$1.59N/A

Aura Biosciences has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Xencor has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

96.8% of Aura Biosciences shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by company insiders. Comparatively, 5.1% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aura Biosciences has a net margin of 0.00% compared to Xencor's net margin of -58.79%. Xencor's return on equity of -21.28% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aura BiosciencesN/A -64.68% -56.08%
Xencor -58.79%-21.28%-15.17%

Aura Biosciences currently has a consensus price target of $17.50, suggesting a potential upside of 144.76%. Xencor has a consensus price target of $42.22, suggesting a potential upside of 22.38%. Given Aura Biosciences' higher probable upside, research analysts clearly believe Aura Biosciences is more favorable than Xencor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Xencor
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64

Summary

Xencor beats Aura Biosciences on 11 of the 15 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AURA vs. The Competition

MetricAura BiosciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$751.42M$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A25.6832.7626.82
Price / SalesN/A16.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book2.594.184.463.72
Net Income-$106.19M-$24.15M$3.52B$393.10M
7 Day Performance-6.54%-7.25%-5.47%-4.73%
1 Month Performance17.21%-5.98%-4.57%-7.14%
1 Year Performance30.00%-7.72%-1.79%-7.51%

Aura Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AURA
Aura Biosciences
2.1883 of 5 stars
$7.15
-1.0%
$17.50
+144.8%
+30.6%$751.42MN/AN/A113
ACAD
ACADIA Pharmaceuticals
4.7411 of 5 stars
$18.28
+10.8%
$31.55
+72.6%
-22.3%$3.15B$1.07B8.66798
IDYA
IDEAYA Biosciences
3.061 of 5 stars
$31.75
-0.9%
$49.55
+56.0%
-5.5%$3.07B$218.71MN/A145
VCEL
Vericel
2.8235 of 5 stars
$59.03
+1.1%
$62.00
+5.0%
+44.2%$3.02B$276.26M92.24398
ZLAB
Zai Lab
3.6286 of 5 stars
$26.43
-1.6%
$37.25
+40.9%
+7.9%$3.01B$460.16MN/A1,784

Related Companies and Tools


This page (NASDAQ:AURA) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners